Primary Site >> Pancreatic Cancer
Gene >> MTOR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. PMID: 10446965 |
Ref: Pathophysiology and Treatment of Pancreatic Neuroendocrine Tumors (PNETs): New Developments PMID: 25905300 |
Ref: FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. PMID: 11341787 |
Ref: Novel protein kinases in pancreatic cell growth and cancer. PMID: 12622411 |
Ref: Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenograf PMID: 15735038 Ref: The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. PMID: 15845392 Ref: Molecularly targeted therapy for gastrointestinal cancer. PMID: 15892618 |
Ref: In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. PMID: 16331623 |
Ref: Endothelial cell KIT expression in human tumours. PMID: 17294421 Ref: Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. PMID: 17333095 Ref: Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. PMID: 17372229 Ref: ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. PMID: 17457047 Ref: Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. PMID: 17968710 Ref: Exploiting novel molecular targets in gastrointestinal cancers. PMID: 17990350 Ref: Suppression of TGF-beta signaling by phospholipase D. PMID: 18032924 Ref: Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. PMID: 18251175 |
Ref: Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. PMID: 17700525 Ref: Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. PMID: 18191814 Ref: Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. PMID: 18245553 Ref: Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. PMID: 18254976 Ref: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. PMID: 18332467 Ref: Pancreatic cancer: from molecular pathogenesis to targeted therapy. PMID: 18427734 Ref: Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? PMID: 18525343 Ref: Biologic therapies for advanced pancreatic cancer. PMID: 18699769 Ref: New treatment options for advanced pancreatic cancer. PMID: 19072345 Ref: [Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells]. PMID: 19080079 Ref: Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. PMID: 19107333 |
Ref: Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. PMID: 19047305 Ref: Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. PMID: 19190347 Ref: New insights into the role of the tuberous sclerosis genes in leukemia. PMID: 19286253 Ref: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. PMID: 19319133 Ref: Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. PMID: 19501590 Ref: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. PMID: 19679549 Ref: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. PMID: 19860903 Ref: Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. PMID: 20009539 |
Ref: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. PMID: 19834494 Ref: Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. PMID: 19901970 Ref: Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. PMID: 20116405 Ref: Enhanced expression of lumican inhibited the attachment and growth of human embryonic kidney 293 cells. PMID: 20138170 Ref: Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. PMID: 20388847 Ref: Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. PMID: 20423485 Ref: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. PMID: 20630061 Ref: DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism. PMID: 20657652 Ref: Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. PMID: 20664591 Ref: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. PMID: 20920162 Ref: Pancreatic endocrine tumors. PMID: 21167379 Ref: CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer. PMID: 21799944 |
Ref: Advances in the systemic treatment of pancreatic neuroendocrine tumors. PMID: 20705397 Ref: Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential. PMID: 20852860 Ref: Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). PMID: 20978368 Ref: Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. PMID: 21087351 Ref: mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. PMID: 21189378 Ref: Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. PMID: 21350002 Ref: Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. PMID: 21492074 Ref: Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. PMID: 21521159 Ref: Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. PMID: 21572398 Ref: Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. PMID: 21593197 Ref: Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. PMID: 21672194 Ref: Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. PMID: 21678117 Ref: Pancreatic neoplasm in 2011: an update. PMID: 21737886 Ref: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. PMID: 21998291 Ref: Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. PMID: 22074495 Ref: Current treatment options for neuroendocrine tumors. PMID: 22076492 Ref: Molecular pathogenesis of pancreatic cancer and clinical perspectives. PMID: 22116519 Ref: Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. PMID: 22292129 Ref: [RAD001 reverses radio-resistance and exerts synergistic tumor inhibition with 5-fluorouracil]. PMID: 22321888 Ref: Emerging therapies in pancreas cancer. PMID: 22811835 |
Ref: A phase 2 study of oral MKC-1, an inhibitor of importin-beta, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. PMID: 21800081 Ref: Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells. PMID: 21840189 Ref: Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. PMID: 21852217 Ref: The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. PMID: 21871555 Ref: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. PMID: 22020918 Ref: A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation. PMID: 22125066 Ref: Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. PMID: 22139427 Ref: The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. PMID: 22170433 Ref: Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis--case report and review of the literature. PMID: 22173120 Ref: Neuroendocrine pancreatic tumors: guidelines for management and update. PMID: 22198808 Ref: Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. PMID: 22211100 Ref: First-line treatment of metastatic pancreatic cancer. PMID: 22406590 Ref: Pancreatic neuroendocrine tumors: entering a new era. PMID: 22406593 Ref: Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. PMID: 22510940 Ref: CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. PMID: 22532602 Ref: FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PMID: 22590527 Ref: Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. PMID: 22726648 Ref: Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. PMID: 22762308 Ref: Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. PMID: 22797357 Ref: Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. PMID: 22797391 Ref: Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. PMID: 22870038 Ref: Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. PMID: 22923165 Ref: Molecular pathology of pancreatic neuroendocrine tumors. PMID: 22943010 Ref: Inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cells is ROS-dependent. PMID: 22946344 Ref: Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancer. PMID: 22949936 Ref: Stromal cell-derived factor 1alpha mediates resistance to mTOR-directed therapy in pancreatic cancer. PMID: 22952422 Ref: The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. PMID: 22986737 Ref: New drugs in the therapy of neuroendocrine tumors. PMID: 23047256 Ref: Systemic treatment of neuroendocrine tumors with hepatic metastases. PMID: 23161287 Ref: The role of AIB1 in breast cancer. PMID: 23226788 Ref: Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. PMID: 23232026 Ref: Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. PMID: 23344033 |
Ref: A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. PMID: 22367239 Ref: Translation of molecular pathways into clinical trials of neuroendocrine tumors. PMID: 22508344 Ref: Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. PMID: 23092266 Ref: mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. PMID: 23149918 Ref: Cucurmosin kills human pancreatic cancer SW-1990 cells in vitro and in vivo. PMID: 23157594 Ref: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. PMID: 23211371 Ref: Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. PMID: 23238993 Ref: Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. PMID: 23251295 Ref: Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. PMID: 23260327 Ref: Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. PMID: 23331005 Ref: Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. PMID: 23361300 Ref: Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PMID: 23437362 Ref: Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. PMID: 23443316 Ref: Targeting the NF-kappaB and mTOR pathways with a quinoxaline urea analog that inhibits IKKbeta for pancreas cancer therapy. PMID: 23444213 Ref: Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion? PMID: 23450148 Ref: Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. PMID: 23455452 Ref: Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. PMID: 23470560 Ref: Systemic treatment for hereditary cancers: a 2012 update. PMID: 23548133 Ref: Targeting the PI3K-AKT-mTOR signaling network in cancer. PMID: 23642907 Ref: Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. PMID: 23659703 Ref: Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. PMID: 23662044 Ref: Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PMID: 23667692 Ref: Practical management of everolimus-related toxicities in patients with advanced solid tumors. PMID: 23689226 Ref: PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. PMID: 23711146 Ref: Drug interactions and the pharmacist: focus on everolimus. PMID: 23757385 Ref: Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PMID: 23825539 Ref: miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the 'minute and miracle' molecule moving as a monitor in the 'genomic galaxy'. PMID: 23834149 Ref: Current understanding of the molecular biology of pancreatic neuroendocrine tumors. PMID: 23840053 Ref: Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. PMID: 23872419 Ref: miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. PMID: 23886294 Ref: Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-beta signalling pathway. PMID: 23950591 Ref: Dietary energy balance modulation of Kras- and Ink4a/Arf+/--driven pancreatic cancer: the role of insulin-like growth factor-I. PMID: 23980075 Ref: Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. PMID: 24003341 Ref: Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. PMID: 24019785 Ref: Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PMID: 24204632 Ref: Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. PMID: 24205284 Ref: PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. PMID: 24209743 Ref: mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. PMID: 24231729 Ref: Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. PMID: 24466367 Ref: PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. PMID: 24624456 |
Ref: Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. PMID: 23241507 Ref: Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. PMID: 23475695 Ref: Pancreatic tumours escape from translational control through 4E-BP1 loss. PMID: 23563181 Ref: The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. PMID: 24198241 Ref: Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. PMID: 24233399 Ref: Systemic therapeutic strategies for GEP-NETS: what can we expect in the future? PMID: 24375390 Ref: [Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation]. PMID: 24405594 Ref: Antagonism of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of rapamycin. PMID: 24461517 Ref: mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. PMID: 24467966 Ref: Antitumor efficacy of alpha-solanine against pancreatic cancer in vitro and in vivo. PMID: 24505326 Ref: Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PMID: 24505341 Ref: Role of autophagy in apoptotic regulation by Akt in pancreatic cancer. PMID: 24510992 Ref: Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. PMID: 24520038 Ref: Mirk/dyrk1B kinase is upregulated following inhibition of mTOR. PMID: 24590896 Ref: Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2. PMID: 24603988 Ref: Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. PMID: 24667713 Ref: Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFbeta1. PMID: 24670043 Ref: Everolimus in advanced solid tumors: when to start, early or late? PMID: 24675508 Ref: Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. PMID: 24685128 Ref: Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth. PMID: 24695460 Ref: Targeting mTOR dependency in pancreatic cancer. PMID: 24717934 Ref: HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. PMID: 24819705 Ref: The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. PMID: 24936056 Ref: BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition. PMID: 24944686 Ref: The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. PMID: 24971544 Ref: Antitumor effect of Kanglaite(R) injection in human pancreatic cancer xenografts. PMID: 25005526 Ref: Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study. PMID: 25029236 Ref: Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. PMID: 25076292 Ref: Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. PMID: 25076330 Ref: Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. PMID: 25143389 Ref: DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. PMID: 25152407 Ref: CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. PMID: 25156567 Ref: Identifying significant crosstalk of pathways in tuberous sclerosis complex. PMID: 25268093 Ref: Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. PMID: 25283354 Ref: GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells. PMID: 25285629 Ref: Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. PMID: 25295009 Ref: Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. PMID: 25297671 Ref: Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors. PMID: 25310565 Ref: Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells. PMID: 25352950 Ref: Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma. PMID: 25425965 Ref: Diabetes, pancreatic cancer, and metformin therapy. PMID: 25426078 Ref: Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. PMID: 25505613 Ref: Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. PMID: 25566081 Ref: Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. PMID: 25688512 |
Ref: Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. PMID: 24469057 Ref: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. PMID: 24791855 Ref: Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. PMID: 24845232 Ref: High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma. PMID: 25079376 Ref: A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. PMID: 25344362 Ref: Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. PMID: 25344906 Ref: mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. PMID: 25442249 Ref: PBI-05204, a supercritical CO(2) extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. PMID: 25476893 Ref: The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. PMID: 25498501 Ref: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. PMID: 25500057 Ref: Sann-Joong-Kuey-Jian-Tang decreases the protein expression of mammalian target of rapamycin but increases microtubule associated protein II light chain 3 expression to inhibit human BxPC3 pancreatic carcinoma cells. PMID: 25516264 Ref: Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. PMID: 25533084 Ref: Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. PMID: 25561726 Ref: Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. PMID: 25576058 Ref: Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. PMID: 25590518 Ref: Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. PMID: 25632222 Ref: Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. PMID: 25632225 Ref: mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. PMID: 25654224 Ref: LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1alpha and Stat3 Signaling. PMID: 25655308 Ref: Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. PMID: 25673820 Ref: Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. PMID: 25736685 Ref: Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. PMID: 25755102 Ref: Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. PMID: 25766633 Ref: Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer. PMID: 25793983 Ref: Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. PMID: 25822310 Ref: Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. PMID: 25834145 Ref: Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. PMID: 25862846 Ref: Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. PMID: 25884680 Ref: Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. PMID: 25901202 Ref: Anticancer Effect of Ginger Extract against Pancreatic Cancer Cells Mainly through Reactive Oxygen Species-Mediated Autotic Cell Death. PMID: 25961833 Ref: Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug. PMID: 25983747 Ref: New targeted therapies in pancreatic cancer. PMID: 26034349 Ref: Effect of Polypurine Reverse Hoogsteen Hairpins on Relevant Cancer Target Genes in Different Human Cell Lines. PMID: 26042602 Ref: MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. PMID: 26046375 Ref: Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. PMID: 26056043 Ref: Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. PMID: 26087898 Ref: Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it. PMID: 26123382 Ref: Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. PMID: 26257206 Ref: The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. PMID: 26284306 Ref: Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids. PMID: 26303708 Ref: Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair. PMID: 26304716 Ref: Rapamycin inhibits the proliferation of SW1990 pancreatic cancer cell. PMID: 26367731 Ref: PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. PMID: 26436951 Ref: PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. PMID: 26451606 Ref: Trametinib and dactolisib but not regorafenib exert antiproliferative effects on rat pancreatic stellate cells. PMID: 26663013 Ref: Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. PMID: 26683340 |
Ref: Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. PMID: 26020105 Ref: Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. PMID: 26643525 Ref: Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. PMID: 26725216 Ref: Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. PMID: 26760500 Ref: Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. PMID: 26804739 Ref: Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. PMID: 26804906 Ref: [Treatment Strategy for Non-Functional Pancreatic Neuroendocrine Tumors (P-NETs) at Kurume University Hospital]. PMID: 26809536 Ref: The Unfolded Protein Response Plays a Predominant Homeostatic Role in Response to Mitochondrial Stress in Pancreatic Stellate Cells. PMID: 26849807 Ref: [Inhibition of Sirolimus on the growth of pancreatic carcinoma and its effect on the expression of glucose transporter and hexokinase ]. PMID: 26875919 Ref: MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. PMID: 26918939 Ref: Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. PMID: 27053503 Ref: ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo. PMID: 27073551 Ref: Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. PMID: 27160287 Ref: ()Epigallocatechin3gallate induces apoptosis in human pancreatic cancer cells via PTEN. PMID: 27176210 Ref: Therapeutic Benefit of Selective Inhibition of p110alpha PI3-Kinase in Pancreatic Neuroendocrine Tumors. PMID: 27225693 Ref: Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition. PMID: 27349387 Ref: The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. PMID: 27357443 Ref: Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. PMID: 27435925 Ref: The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. PMID: 27539383 Ref: CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. PMID: 27542220 Ref: KRAS-related proteins in pancreatic cancer. PMID: 27595930 Ref: Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. PMID: 27613577 Ref: Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. PMID: 27615706 Ref: The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients. PMID: 27666620 Ref: Interplay between cell cycle and autophagy induced by boswellic acid analog. PMID: 27680387 Ref: Phycocyanin Inhibits Tumorigenic Potential of Pancreatic Cancer Cells: Role of Apoptosis and Autophagy. PMID: 27694919 Ref: mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. PMID: 27758884 Ref: HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. PMID: 27793006 Ref: Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. PMID: 27919956 Ref: Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line. PMID: 28217402 |
Ref: Hyaluronan carried by tumor-derived microvesicles induces IL-10 production in classical (CD14(++)CD16(-)) monocytes via PI3K/Akt/mTOR-dependent signalling pathway. PMID: 26210045 Ref: IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. PMID: 28069799 Ref: Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. PMID: 28143872 Ref: Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G2 /M Arrest. PMID: 28165150 Ref: Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. PMID: 28176634 Ref: Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing. PMID: 28179320 Ref: Emerging protein kinase inhibitors for treating pancreatic cancer. PMID: 28253828 Ref: A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors. PMID: 28295876 Ref: Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. PMID: 28315323 Ref: Engineered Resistant-Starch (ERS) Diet Shapes Colon Microbiota Profile in Parallel with the Retardation of Tumor Growth in In Vitro and In Vivo Pancreatic Cancer Models. PMID: 28346394 Ref: A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. PMID: 28350132 Ref: The role of stromal cancer-associated fibroblasts in pancreatic cancer. PMID: 28351381 Ref: Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. PMID: 28377226 Ref: A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. PMID: 28442920 Ref: Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. PMID: 28445935 Ref: microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. PMID: 28450156 Ref: Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? PMID: 28454119 Ref: Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. PMID: 28513565 Ref: Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. PMID: 28574828 Ref: BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. PMID: 28591720 Ref: Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges. PMID: 28705806 Ref: Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. PMID: 28801576 Ref: alpha, gamma-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines. PMID: 28822990 Ref: Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases. PMID: 28860807 Ref: mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment. PMID: 28864682 Ref: A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling. PMID: 28870807 Ref: A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. PMID: 28899863 Ref: mTOR Inhibition Restores Amino Acid Balance in Cells Dependent on Catabolism of Extracellular Protein. PMID: 28918901 Ref: Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa. PMID: 28947153 Ref: Hypoxia-Targeting, Tumor Microenvironment Responsive Nanocluster Bomb for Radical-Enhanced Radiotherapy. PMID: 28992409 Ref: Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry. PMID: 29018223 Ref: miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. PMID: 29078789 Ref: PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? PMID: 29093603 Ref: Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. PMID: 29156703 Ref: Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. PMID: 29204055 Ref: Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. PMID: 29212165 Ref: The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. PMID: 29228674 Ref: Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL. PMID: 29233971 Ref: Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling. PMID: 29262554 Ref: Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. PMID: 29262588 Ref: The tyrosine kinase inhibitors effects on metastatic tumor graft in the chick chorioallantoic membrane assay. PMID: 29556614 |
Ref: Expanding the Spectrum of Colonic Manifestations in Tuberous Sclerosis: L-Cell Neuroendocrine Tumor Arising in the Background of Rectal PEComa. PMID: 28733877 Ref: Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells. PMID: 29051320 Ref: Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. PMID: 29321190 Ref: MTOR inhibitor-based combination therapies for pancreatic cancer. PMID: 29384525 Ref: Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway. PMID: 29386088 Ref: Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells. PMID: 29434218 Ref: Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. PMID: 29434877 Ref: Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway. PMID: 29434909 Ref: MiR-1271 negatively regulates AKT/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer. PMID: 29461595 Ref: Metformin influences drug sensitivity in pancreatic cancer cells. PMID: 29482945 Ref: Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. PMID: 29521944 Ref: Gut microbiota and mTOR signaling: Insight on a new pathophysiological interaction. PMID: 29548696 Ref: Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. PMID: 29575133 Ref: Management of functional neuroendocrine tumors of the pancreas. PMID: 29629316 Ref: Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia. PMID: 29684618 Ref: A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. PMID: 29757973 Ref: Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells. PMID: 29781033 Ref: Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells. PMID: 29978609 Ref: Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. PMID: 29980405 Ref: Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway. PMID: 30008887 Ref: The IGF pathway is activated in insulinomas but downregulated in metastatic disease. PMID: 30021864 Ref: Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. PMID: 30021865 Ref: Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. PMID: 30046371 Ref: Everolimus. PMID: 30069763 Ref: Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line. PMID: 30070833 Ref: Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. PMID: 30142009 Ref: Tanshinone IIA can inhibit MiaPaCa2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways. PMID: 30226540 Ref: A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors. PMID: 30254185 Ref: Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells. PMID: 30261145 Ref: Mahanimbine Exerts Anticancer Effects on Human Pancreatic Cancer Cells by Triggering Cell Cycle Arrest, Apoptosis, and Modulation of AKT/Mammalian Target of Rapamycin (mTOR) and Signal Transducer and Activator of Transcription 3 (STAT3) Signalling Pathway PMID: 30273298 Ref: Ancistrolikokine E3, a 5,8'-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway. PMID: 30303002 Ref: Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. PMID: 30323244 Ref: Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. PMID: 30323973 |